CD274 and cancer: Therefore, the design of new PD‐L1 antibodies for cancer treatment should be considered to exclusively inhibit PD‐L1 trans interactions while sparing the cis interaction with the CD80‐epitope, allowing for both T cell priming and prolonged activation.